UNSPSC 51282322: Erythromycin lactobionate

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO13.C12H22O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33H58I7GLQ, chemically known as erythromycin, n-demethyl-n-(methyl-11c)- but more generally known as erythromycin lactobionate, which bears US NIH Compound Identifier 12560. European Medicines Agency schedules Erythromycin lactobionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01944MIG.

Most nations, for tariff and trade purposes, schedule erythromycin lactobionate under HS 29415000 and SITC 54139. Erythromycin lactobionate bears US NLM identifiers UMLS ID C0059562 and NCI Concept Code C47988. SMILES: As of Q4 2014, ERYTHROMYCIN LACTOBIONATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51282322 Erythromycin lactobionate is a Commodity code that sits within the broader pharmaceutical products taxonomy, but the recent state and local opportunities tagged under it do not reflect purchases of erythromycin lactobionate specifically. Instead, the posted solicitations show state and local health agencies procuring other pharmaceutical products — antibiotics such as doxycycline and ciprofloxacin, and public-health supplies including naloxone and drug deactivation systems. The code's nominal scope and the actual purchasing activity diverge significantly, suggesting either miscategorization in the state and local procurement systems or a shift in how agencies are tagging pharmaceutical commodity buys. When erythromycin lactobionate is procured by state and local bodies, it typically flows through cooperative purchasing vehicles and piggyback contracts with established pharmaceutical distributors rather than through direct open solicitation.

Recent activity shows Illinois Department of Public Health and Seminole County, Florida as the issuing bodies in the available record. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for antibiotic products ($2,999,999.11 over the contract life, initial 12-month term with two renewal options). Seminole County released an IFB in June 2026 for naloxone and safe drug deactivation systems with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date and likely reflects a data error in the source). No open solicitations specifically for erythromycin lactobionate appear in the recent record, and the code shows limited relevant purchasing activity in the current state and local procurement pipeline.